Multinational phase 3 study of pembrolizumab for persistent, recurrent, or metastatic cervical cancer
Dr. Nicoletta Colombo
The multinational phase 3 KEYNOTE-826 trial evaluated addition of pembrolizumab versus placebo to platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. Progression-free and overall survival were significantly longer with pembrolizumab than with placebo, both in patients with PD-L1 combined positive score of 1 and more, and in the ITT population. The most common grade 3 to 5 adverse events were anemia (30.3% of patients in the pembrolizumab group and 26.9% in the placebo group) and neutropenia (12.4% and 9.7%, respectively).
